|
|
Abbott Laboratories (ABT) |
|
|
|
| |
ABT's Revenue Growth by Quarter and Year
Abbott Laboratories's Revenue results by quarter and year
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
| ABT Revenue (in millions $) |
FY 2023 |
FY 2022 |
FY 2021 |
FY 2020 |
| IV Quarter |
December |
-
|
10,091.00
|
11,468.00
|
10,701.00
|
| III Quarter |
September |
-
|
10,410.00
|
10,928.00
|
8,853.00
|
| II Quarter |
June |
9,978.00
|
11,257.00
|
10,223.00
|
7,328.00
|
| I Quarter |
March |
9,747.00
|
11,895.00
|
10,456.00
|
7,726.00
|
| FY |
|
19,725.00
|
43,653.00
|
43,075.00
|
34,608.00
|
| ABT Revenue second quarter 2023 Y/Y Growth Comment |
Abbott Laboratories reported fall in Revenue in the second quarter 2023 by -11.36% to $ 9,978.00 millions, from the same quarter in 2022.
The decline in the second quarter 2023 Abbott Laboratories's Revenue compares unfavorably to the Company's average Revenue growth of 5.6%.
Looking into second quarter 2023 results within Major Pharmaceutical Preparations industry 37 other companies have achieved higher Revenue growth. While Abbott Laboratories' s Revenue decrease of -11.36% ranks overall at the positon no. 1110 in the second quarter 2023.
|
| ABT Revenue ( Y/Y Growth %) |
2023
|
2022 |
2021 |
2020 |
| IV Quarter |
December |
- |
-12.01 % |
7.17 % |
28.71 % |
| III Quarter |
September |
- |
-4.74 % |
23.44 % |
9.62 % |
| II Quarter |
June |
-11.36 % |
10.11 % |
39.51 % |
-8.16 % |
| I Quarter |
March |
-18.06 % |
13.76 % |
35.34 % |
2.53 % |
| FY |
|
- |
1.34 % |
24.47 % |
8.48 % |
ABT Revenue (Quarter on Quarter Growth %) |
2023
|
2022 |
2021 |
2020 |
| IV Quarter |
December |
- |
-3.06 % |
4.94 % |
20.87 % |
| III Quarter |
September |
- |
-7.52 % |
6.9 % |
20.81 % |
| II Quarter |
June |
2.37 % |
-5.36 % |
-2.23 % |
-5.15 % |
| I Quarter |
March |
-3.41 % |
3.72 % |
-2.29 % |
-7.07 % |
| FY (Year on Year) |
|
- |
1.34 % |
24.47 % |
8.48 % |
| Revenue Y/Y Growth Statistics |
| High |
Average |
Low |
| 31.35 % |
5.6 % |
-39.34 % |
| (Dec 31 2017) |
|
(March 31, 2014) |
|
|
| Revenue Y/Y Growth Statistics |
| High |
Average |
Low |
| 31.35 % |
5.6 % |
-39.34 % |
| (Dec 31 2017) |
|
(March 31, 2014) |
|
| Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023 |
Abbott Laboratories's Q/Q Revenue Growth
| Revenue Q/Q Growth Statistics |
| High |
Average |
Low |
| 85.61 % |
1.91 % |
-50.37 % |
| (June 30. 2012) |
|
|
| ABT's II. Quarter Q/Q Revenue Comment |
Abbott Laboratories achieved in the II. Quarter 2023 above company average sequential Revenue growth of 2.37%, to $ 9,978.00 millions, from $9,747.00 millions in the first quarter.
ABT is going from strength to strength, not just claiming better then average increase, but also improving pace, Ritvik Malhotra , market researcher said.
Within Major Pharmaceutical Preparations industry 44 other companies have achieved higher Revenue quarter on quarter growth. While Abbott Laboratories's Revenue growth quarter on quarter, overall rank is 843. |
|
|
|
| Revenue Q/Q Growth Statistics |
| High |
Average |
Low |
| 85.61 % |
1.91 % |
-50.37 % |
| (June 30. 2012) |
|
|
| ABT's II. Quarter Q/Q Revenue Comment |
Abbott Laboratories achieved in the II. Quarter 2023 above company average sequential Revenue growth of 2.37%, to $ 9,978.00 millions, from $9,747.00 millions in the first quarter.
ABT is undergoing a remarkable growth, not only claiming higher then normal increase, but also improving speed.
Within Major Pharmaceutical Preparations industry 44 other companies have achieved higher Revenue quarter on quarter growth. While Abbott Laboratories's Revenue growth quarter on quarter, overall rank is 843. |
|
Abbott Laboratories's 12 Months Revenue Growth Year on Year
Revenue TTM Growth |
12 Months Ending
(Jun 30 2023) |
12 Months Ending
(Mar 31 2023) |
12 Months Ending
(Dec 31 2022) |
12 Months Ending
(Sep 30 2022) |
12 Months Ending
(Jun 30 2022) |
| Cumulative Revenue 12 Months Ending |
$ 40,226.00 |
$ 41,505.00 |
$ 43,653.00 |
$ 45,030.00 |
$ 45,548.00 |
| Y / Y Revenue Growth (TTM) |
-11.68 % |
-6.76 % |
1.34 % |
6.43 % |
13.21 % |
| Year on Year Revenue Growth Overall
Ranking |
# 1280 |
# 1090 |
# 793 |
# 1841 |
# 1836 |
| Seqeuential Revenue Change (TTM) |
-3.08 % |
-4.92 % |
-3.06 % |
-1.14 % |
2.32 % |
| Seq. Revenue Growth (TTM) Overall
Ranking |
# 1110 |
# 2289 |
# 2147 |
# 2851 |
# 2118 |
| Cumulative Revenue growth
Comment |
Abbott Laboratories's cumulative 12 months Revenue continue to fall, but on the faster rate at -11.68% year on year, at Jun 30 2023 compare to the -6.76% decrease at Mar 31 2023. If the Abbott Laboratories's fiscal year would end at Jun 30 2023, annual Revenue would be $40,226 millions.
In the Healthcare sector 251 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1090 to 1280. |
| Revenue TTM Q/Q Growth Statistics |
| High |
Average |
Low |
31.35 % |
5.6 % |
-39.34 % |
|
|
|
|
|
| Revenue TTM Y/Y Growth Statistics |
| High |
Average |
Low |
31.35 % |
5.6 % |
-39.34 % |
|
|
|
| Revenue TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 38 |
| Sector |
# 117 |
| S&P 500 |
# 1110 |
|
| Cumulative Revenue growth
Comment |
Abbott Laboratories's cumulative 12 months Revenue continue to fall, but on the faster rate at -11.68% year on year, at Jun 30 2023 compare to the -6.76% decrease at Mar 31 2023. If the Abbott Laboratories's fiscal year would end at Jun 30 2023, annual Revenue would be $40,226 millions.
In the Healthcare sector 251 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1090 to 1280. |
| Revenue TTM Q/Q Growth Statistics |
| High |
Average |
Low |
31.35 % |
5.6 % |
-39.34 % |
|
|
|
| Revenue TTM Y/Y Growth Statistics |
| High |
Average |
Low |
31.35 % |
5.6 % |
-39.34 % |
|
|
|
| Revenue TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 38 |
| Sector |
# 117 |
| S&P 500 |
# 1110 |
|
